A phase II study of thalidomide in advanced metastatic renal cell carcinoma

Investigational New Drugs

Volumn 20, Issue 4, 2002, Pages 389-393

  Minor, David R ^a,b,c   Monroe, Dana ^a,b,c   Damico, Lisa A ^a,b,c   Meng, Gloria ^a,b,c   Suryadevara, Uma ^a,b,c   Elias, Laurence ^a,b,c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

Angiogenesis; Renal cell carcinoma; Thalidomide; Thalomid; Vascular endothelial growth factor; VEGF

Indexed keywords

ALPHA INTERFERON; FLUOXYMESTERONE; INTERLEUKIN 2; MEGESTROL; MONOCLONAL ANTIBODY; THALIDOMIDE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SOMNOLENCE; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ADULT; AGED; CARCINOMA, RENAL CELL; CONSTIPATION; DISORDERS OF EXCESSIVE SOMNOLENCE; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036828582     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020669705369     Document Type: Article

References (19)

1. Mellin GW, Katzenstein M: The sage of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies. N Eng J Med 267:1238-1244, 1962
2. Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26(5):351-362, 2000
3. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 341:1565-1571, 1999
4. Calabrese L, Fleischer AB: Thalidomide: Current and potential clinical applications. Amer J Med 108(6):487-495, 2000
5. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Onc 18:708-715, 2000
6. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigel E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593-2602, 2000
7. Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginB complex: Implications for VHL tumor suppressor function. Science 284:455-461, 1999
8. Blay JY, Pallardy M, Ravaud A: Serum VEGF is an independent prognostic factor in patients (pts) with metastatic renal cell carcinoma treated with IL-2 and/or IFN: Analysis of the CRECY trial. Proc Amer Soc Clin Onc 18:1669, 1999
9. , D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085, 1994
10. Zeldis JB, Williams BA, Thomas SD, Elsayed ME, S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319-330, 1999
11. Rodriguez CR, Fei DT, Keyt B, Baly DL: A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma. J Immunological Methods 219:45-55, 1998
12. Eisen T, Boshoff C, Mak I: Continuous low dose Thalidonide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Brit J Cancer 82(4):812-817, 2000
13. Escudier B, Lassau N, Couanet D, Angevin E, Leborgne S, Garofano A, Mesrati F, Laplanche A: A phase II trial of Thalidomide in renal cell carcinoma. Proc Amer Soc Clin Onc 20:180a, (abstr 718), 2001
14. Li Z, Amato R, Papandreou C, Pagliaro L, Kim J, Millikan R, Loggins-Coffman J, Perez C, Logothesis C, Dalani D: Phase II Study of Thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc Amer Soc Clin Onc 20:180a, (abstr 717), 2001
15. Novik Y, Dutcher JP, Larkin M, Wiernik P: Phase II study of Thalidomide(T) in advanced refractory metastatic renal cell cancer (MRCC): A single institution experience. Proc Amer Soc Clin Onc 20:265a, (abstr 1057), 2001
16. Vuky J, Berg W, Yu R, Ginsberg M, Mazumdar M, Bacik J, Motzer R: Phase II trial of Thalidomide in patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Onc 20:265a, (abstr 1056), 2001
17. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953-958, 2001
18. Zangari M, Anissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001
19. Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A: Thalidomide and venous thrombosis. Ann Int Med 136:711-712, 2002